Skip to content

13F-HR filed by Consonance Capital Management LP

Consonance Capital Management LP filed this 13F-HR for the quarter ended 2018-03-31, filed 2018-05-15, with 26 holding rows worth $1,094,287,000.

Accession
0001085146-18-001443
Filed
2018-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2018

A holdings report, 26 entries on the cover page, a total value of $1,094,287,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,094,287,000 with VALUE read as thousands by filing date, 13F file number 028-14924. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
RADIUS HEALTH INC750469207COM NEW2,900,893$104,258,000thousands by filing date
SPECTRUM PHARMACEUTICALS INC84763A108COM6,203,356$99,812,000thousands by filing date
CORCEPT THERAPEUTICS INC218352102COM5,188,417$85,349,000thousands by filing date
RETROPHIN INC761299106COM3,693,371$82,584,000thousands by filing date
PACIRA BIOSCIENCES INC COM695127100Stock2,634,916$82,078,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock566,926$63,700,000thousands by filing date
NUVASIVE INC670704105COM1,099,523$57,406,000thousands by filing date
UROGEN PHARMA LTDM96088105COMMON STOCK1,146,197$56,955,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM3,206,073$54,183,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW17,729,933$53,367,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM3,072,275$51,768,000thousands by filing date
STEMLINE THERAPEUTICS INC85858C107COM2,606,598$39,881,000thousands by filing date
DYNAVAX TECHNOLOGIES CORP268158201COM NEW1,658,795$32,927,000thousands by filing date
VERICEL CORP92346J108COM3,104,592$30,891,000thousands by filing date
GW PHARMACEUTICALS PLC36197T103ADS272,700$30,725,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS2,339,184$29,123,000thousands by filing date
PACIFIC BIOSCIENCES CALIF INC COM69404D108Stock12,576,002$25,781,000thousands by filing date
SAVARA INC805111101COM2,711,190$24,943,000thousands by filing date
UNIQURE NVN90064101SHS1,045,065$24,559,000thousands by filing date
ADMA BIOLOGICS INC000899104COM3,329,234$15,314,000thousands by filing date
CATALYST PHARMACEUTICALS INC14888U101COM4,994,719$11,937,000thousands by filing date
CARDIOVASCULAR SYSTEMS INC141619106COMMON STOCK446,100$9,783,000thousands by filing date
ANI PHARMACEUTICALS INC00182C103COM142,943$8,322,000thousands by filing date
RA PHARMACEUTICALS INC74933V108COM1,454,761$7,725,000thousands by filing date
CORINDUS VASCULAR ROBOTICS I218730109COM4,574,835$6,268,000thousands by filing date
FLEXION THERAPEUTICS INC33938J106COM207,392$4,648,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001085146-18-001443this filing2018-05-15acceptance time not in the bulk data set